Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Sep;7(Suppl 6):S187.
doi: 10.21037/atm.2019.07.48.

The importance of not only living longer but also better in the setting of advanced urothelial cancer

Haris Zahoor  1 , Petros Grivas  2   3
Affiliations
Editorial

The importance of not only living longer but also better in the setting of advanced urothelial cancer

Haris Zahoor et al. Ann Transl Med. 2019 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: H Zahoor: reports honoraria and advisory board activity for Exelixis. P Grivas: (all unrelated in the last 3 years): consulting (AstraZeneca; Bayer; Biocept; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Driver; EMD Serono; Exelixis; Foundation Medicine; Genentech; Heron Therapeutics; Janssen; Merck & Co.; Mirati Therapeutics; Pfizer; Seattle Genetics; QED Therapeutics); educational program: [(not current): Bristol-Myers Squibb; Genentech]; Research Funding to Institution (AstraZeneca, Bayer; Genentech/Roche; Merck & Co.; Mirati Therapeutics; Oncogenex; Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb).

Comment on

References

    1. Pickard AS, Jiang R, Lin HW, et al. Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. Clin Ther 2016;38:769-77. 10.1016/j.clinthera.2016.03.009 - DOI - PubMed
    1. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376:1015-26. 10.1056/NEJMoa1613683 - DOI - PMC - PubMed
    1. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20. 10.1016/S0140-6736(16)00561-4 - DOI - PMC - PubMed
    1. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312-22. 10.1016/S1470-2045(17)30065-7 - DOI - PubMed
    1. Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 2016;34:3119-25. 10.1200/JCO.2016.67.9761 - DOI - PMC - PubMed